Bayer upgraded to Buy from Neutral at Goldman Sachs

Goldman Sachs analyst James Quigley upgraded Bayer (BAYRY) to Buy from Neutral with a EUR 33 price target The stock’s risk/reward into the second half of 2025 looks positive and catalysts could support a re-rating over the medium term, the analyst tells investors in a research note. The firm says that following a strong start to the year operationally, with cost discipline in Crop and strong momentum in the underlying Pharma business, Bayer may have reached the bottom of the negative earnings revision cycle.